Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Policy & Acquisitions

Mergers & Acquisitions

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Mergers & Acquisitions

214 stories · every one Fact-Checked
Top view of glass covered tubes arranged on table near plastic stand with tubes placed on row in modern laboratoryMergers & AcquisitionsIncyte Bolsters Hematology Growth With $2 Billion Vega BuyoutIncyte has agreed to acquire Vega Therapeutics for up to $2 billion, gaining VGA039, a first-in-class anti-Protein S monoclonal antibody in Phase 3 development for von Willebrand disease.…8 Jun 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_ppje3uppje3uppjeMergers & AcquisitionsAlnylam Partners With Inceptive in Up to $2 Billion AI Drug Discovery DealAlnylam Pharmaceuticals has partnered with Inceptive Nucleics in a deal worth up to $2 billion to advance RNAi therapeutics through AI‑driven design.4 Jun 2026 · 3 min read
Fact-Checked
Scientists conducting research in a state-of-the-art laboratory with advanced equipment.Mergers & AcquisitionsIDEAYA and Roche Advance PRMT5 and Pan-RAS Inhibitors in Pancreatic CancerIDEAYA Biosciences and Roche have partnered to evaluate the PRMT5 inhibitor IDE892 with the pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.4 Jun 2026 · 2 min read
Fact-Checked
Scientist in a lab coat handling samples for scientific research in a modern laboratory setting.Mergers & AcquisitionsAscidian Secures Up to $1.9 Billion in Lilly Kidney Disease PartnershipEli Lilly has entered a $1.9 billion collaboration with Ascidian Therapeutics to advance RNA exon editing therapies for monogenic kidney diseases.4 Jun 2026 · 3 min read
Fact-Checked
cytomxMergers & AcquisitionsCytomX Secures Expanded Regeneron Partnership Worth Up to $4 BillionCytomX Therapeutics and Regeneron Pharmaceuticals have broadened their 2022 oncology collaboration, adding new targets and strengthening efforts to advance conditionally activated bispecific immunotherapies designed to improve safety and…3 Jun 2026 · 3 min read
Fact-Checked
Close-up of hands organizing vials and syringe in a medical first aid kit, emphasizing emergency readiness.Mergers & AcquisitionsCEPI Backs Moderna’s Bundibugyo Ebola Vaccine with $50 MillionModerna has expanded its collaboration with CEPI to accelerate development of an investigational mRNA vaccine against Bundibugyo ebolavirus.2 Jun 2026 · 3 min read
Fact-Checked
Close-up of a businessman reading a newspaper indoors, focusing on business headlines.Mergers & AcquisitionsServier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 BillionServier has agreed to acquire Edgewise Therapeutics’ muscular dystrophy business for up to $2.65 billion, securing late-stage investigational therapy sevasemten for Becker and Duchenne muscular dystrophies.2 Jun 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_5gaai45gaai45gaaMergers & AcquisitionsAgios Lands Global Cevidoplenib Rights in Rare Hematology PushAgios Pharmaceuticals has secured worldwide rights to cevidoplenib, a next‑generation SYK inhibitor from Oscotec, in a $25 million licensing deal with milestone and royalty potential.1 Jun 2026 · 3 min read
Fact-Checked
2163Mergers & AcquisitionsPfizer and Innovent Strike Oncology Deal Worth Up to $10.5 BillionPfizer and Innovent Biologics have formed a global oncology partnership worth up to $10.5 billion to advance 12 early-stage cancer programs spanning antibody-drug conjugates and multispecific antibodies.29 May 2026 · 3 min read
Fact-Checked
Decorative cardboard appliques representing piles of banknotes between hands of business partners on violet backgroundMergers & AcquisitionsApogee Secures Up to $1.3 Billion From Blackstone to Advance Zumilokibart in Atopic DermatitisApogee Therapeutics has entered a strategic financing agreement with Blackstone Life Sciences valued at up to $1.3 billion, combining synthetic royalty funding and optional senior debt to support…27 May 2026 · 2 min read
Fact-Checked
Syringe and vaccine vials with 'vaccine' text on a gray background, representing vaccination efforts.Mergers & AcquisitionsLilly Acquires Curevo, LimmaTech, and Vaccine Company to Expand Vaccine PortfolioEli Lilly and Company will acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc.26 May 2026 · 3 min read
Fact-Checked
patrick-assale-UH2x_pfV4MA-unsplashMergers & AcquisitionsGilead Renews WHO Partnership to Fight Visceral LeishmaniasisGilead Sciences and the World Health Organization have expanded their collaboration to combat visceral leishmaniasis (VL), one of the world’s deadliest neglected tropical diseases.21 May 2026 · 3 min read
Fact-Checked
Page 11 of 18